American Medical Innovation and Investment Act of 2024
Latest Action
Reported (Amended) by the Committee on Ways and Means. H. Rept. 118-958, Part I.
Official Summary
Official summary has not been imported yet.
GovScope Watchdog™
AI Government Intelligence™The American Medical Innovation and Investment Act of 2024 is a House bill from the 118th Congress focused on health policy. The bill was reported as amended by the Committee on Ways and Means but ultimately failed or expired without becoming law. Specific details about the bill's provisions, including its objectives, mechanisms, and funding, are not available in the provided source data. The bill's legislative activity concluded with a committee report dated December 27, 2024.
This health-related bill aimed at medical innovation and investment did not advance beyond committee consideration and expired without enactment.
- The bill is titled the American Medical Innovation and Investment Act of 2024 and was introduced in the House of Representatives.
- It was reported with amendments by the Committee on Ways and Means, indicating some level of committee review and modification.
- The bill ultimately failed or expired, meaning it did not pass into law during the 118th Congress.
['Potential beneficiaries could include medical researchers, healthcare innovators, investment entities in the medical sector, and possibly patients, though specific beneficiaries cannot be identified due to lack of detailed bill text.']
['Without the full text, it is unclear what implementation challenges, costs, or oversight mechanisms the bill proposed.', 'The failure to advance beyond committee suggests possible concerns or lack of consensus among lawmakers.', 'The absence of detailed provisions limits assessment of authority delegation or policy tradeoffs.']
The bill was considered during the 118th Congress and was subject to committee review by the House Committee on Ways and Means. The committee issued a report with amendments, but the bill did not progress to a floor vote or enactment. This status reflects the legislative process where many bills do not become law.
No hidden impact flags detected
GovScope reviewed 0 policy-risk categories. Hover for a quick definition. Click detected flags for bill-specific details.
GovScope did not receive a hidden-impact review for this bill.
['If enacted, the bill could have influenced investment flows into medical innovation sectors, potentially affecting research and development priorities.', "The bill's failure to pass may maintain the status quo in medical innovation funding and policy."]
The absence of a bill summary and full text limits transparency and public understanding of the bill's content and implications. The committee report referenced (H. Rept. 118-958, Part I) may provide additional details but is not included here. Tracking such reports is important for comprehensive oversight.
GovScope Intelligence Roadmap
Future bill intelligence will connect sponsors, committee referrals, related votes, campaign finance, disclosures, and stock trades into one legislative intelligence view.